@bluebonnet242,
the article may not even interest you. It's just some speculation about bisphosphonates.
Clinical trials on Fotteo were limited to 24 months. I don't know of any trials ensuing after the cancer warning was removed. Physicians are left to determine which patients would benefit from extended use.
Ten year follow-up of women who stopped Forteo after 18 month indicates a sustained fracture protection while BMD returned to baseline gradually over those ten years. Though those women took either HRT or alendronate.
After taking Forteo the cells that build bone proliferate. Their activity stimulates the cells that break bone down. Eventually the osteoclasts can dominate in number though there isn't evidence of disadvantage in this.
The assumption comes from a time before Forteo when the only pharmaceutical control was to reduce osteoclasts.
But we can use bone markers to determine the relation between osteoclasts and osteoblasts on an individual basis in our own treatment.
So far it appears as though continued use of Forteo doesn't just maintain gains but advances them.